Sign in to view content

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: Phase 2 LUNA Study Update

Glenn C. Yiu, MD, PhD

Video
Published 2025

Related

1-Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ABBV-RGX-314 for Neovascular AMD
Robert L. Avery, MD
Updates from the Field
2025
Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First-Time 26-Week Interim Analysis Results From the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2024
Interim Results of the Phase 1-2 PRISM Trial Evaluating 4D-150 a Dual-Transgene Intravitreal Genetic Medicine for Neovascular (Wet) Age-Related Macular Degeneration
Christine Kay, MD
Annual Meeting Talks
2023

Category: AMD-Neovascular

See more